Acute myeloid leukemia

AML affects myeloid blood-forming cells and can cause anemia, infection and bleeding. Diagnosis combines blood and marrow morphology, flow cytometry, chromosome analysis and molecular tests. A white-cell count need not be high. Blast percentage must be interpreted alongside defining genetic abnormalities; a simple universal 20% rule is not sufficient for every modern category.

The integrated report should specify the classification system and abnormalities such as PML::RARA, core-binding-factor fusions, NPM1, relevant CEBPA variants, TP53 and myelodysplasia-related changes. A history of MDS/MPN, previous cancer therapy or suspected inherited predisposition adds important context.

Suspected acute promyelocytic leukemia with a coagulopathy needs immediate hospital management, rapid PML::RARA testing and specialist-directed treatment before all confirmatory results return. Bleeding support is urgent. Patients should not wait for travel, a distant consultation or a complete elective work-up.

ATRA and arsenic-based treatment are central, with the regimen adjusted for presenting risk and complications. The APOLLO randomized trial supports ATRA–arsenic with limited idarubicin in high-risk APL; this is not a reason to omit all cytoreduction in high-risk patients. Differentiation syndrome, white-cell rise, QT prolongation and electrolytes require active monitoring.

ELN genetic risk helps frame relapse risk and post-remission planning. The 2022 framework largely reflects intensive treatment, while the 2024 ELN less-intensive framework was developed for defined hypomethylating-agent-based approaches. A risk label should therefore include the treatment context rather than be treated as an immutable personal prognosis.

Fitness includes heart, lung, liver and kidney function, frailty, other illnesses, infection and patient priorities. Age alone does not decide intensity or transplant eligibility. Early supportive care can stabilize a patient while rapid genetic results guide the safest effective regimen.

Intensive induction commonly uses cytarabine and an anthracycline, with subtype-specific additions or alternative formulations when appropriate. Azacitidine–venetoclax is established for many patients unsuitable for intensive induction; the US venetoclax AML label specifies newly diagnosed adults aged 75 or older, or adults with comorbidities that preclude intensive induction, in specified combinations.

The September 2026 PARADIGM randomized phase II report found longer event-free survival with azacitidine–venetoclax than induction chemotherapy in its induction-eligible study population. This is important evidence for individualized discussion, not proof that it replaces every intensive or molecularly matched regimen. Trial eligibility, comparator and the subsequent transplant strategy matter.

Venetoclax combinations can cause prolonged cytopenias and serious infection. Early marrow response assessment, cycle timing and drug interactions—especially with some antifungals—guide modifications. Lower intensity does not mean unsupervised oral treatment or a fixed schedule regardless of recovery.

Targets and drugs are not interchangeable. FLT3-ITD and FLT3-TKD, for example, do not confer the same eligibility for every inhibitor. ECG monitoring, differentiation syndrome, hepatic toxicity and interactions differ by agent. The US quizartinib label specifically does not indicate maintenance monotherapy after allogeneic transplantation.

Revumenib has a US indication for relapsed/refractory acute leukemia with a KMT2A translocation from age one year. Its separate NPM1-mutated AML indication also starts at age one year and requires no satisfactory alternative. Ziftomenib is US-approved for adults with relapsed/refractory AML carrying a susceptible NPM1 mutation and no satisfactory alternative.

These are specific molecular and treatment-line indications, not approvals for all newly diagnosed AML or every KMT2A abnormality. Differentiation syndrome and other drug-specific risks require specialist monitoring. Combination studies may broaden their role, but a trial regimen and the current approved indication should remain clearly separated.

The 2025 ELN-DAVID update, published in 2026, tailors MRD assessment to genetic and prognostic subgroups. Molecular markers such as NPM1 or fusion transcripts and flow cytometry answer different questions. Sampling quality, sensitivity and timing matter; persistence of some clonal-hematopoiesis mutations does not by itself equal persisting AML.

After remission, options include consolidation, allogeneic transplantation or a defined maintenance approach. Oral azacitidine is used in a specific continued-treatment setting after intensive induction when further intensive curative therapy cannot be completed. It must not be substituted for injectable azacitidine: the formulations, schedules and supporting evidence differ.

Transplant decisions weigh genetic relapse risk, MRD, disease control, organ function and donor options against treatment-related mortality and graft-versus-host disease. Donor work-up may start early when transplant is likely. MRD positivity increases concern but is not a standalone reason to deny every transplant.

Relapse requires repeat marrow and genetic assessment because actionable clones can change. Salvage chemotherapy, a matched inhibitor, a trial and subsequent transplantation may be considered. Relapse after transplant adds questions about immune suppression, donor lymphocytes and second transplant; these require an experienced transplant team.

AML CAR-T is not equivalent to established CD19 therapy in B-ALL. AML targets may overlap normal myeloid cells, and persistent marrow suppression and infection complicate treatment. The target profile and the planned rescue or transplant strategy are central to trial eligibility.

Recent prospective reports include 2026 CLL-1-directed KITE-222, donor-derived CD33 VCAR33 after transplantation and base-edited BE-CAR33 before transplantation. These are early studies with different designs and populations. They establish clinical research activity, not a proven universally available AML CAR-T standard.

Fever, uncontrolled bleeding, new breathing difficulty or confusion during treatment needs immediate assessment. Infection prophylaxis, blood products, tumor-lysis prevention, fertility discussion and symptom management belong in the treatment plan. Children require pediatric AML expertise rather than direct use of adult risk tables and dosing.

Bring the complete integrated diagnosis, chromosome and mutation reports, serial marrow/MRD results, all treatment dates and responses, severe infections, prior radiation/chemotherapy and transplant information. The most useful question is which finding would change the next decision, and what the fallback plan is if remission is not achieved.